论文部分内容阅读
目的 探讨多柔比星-五味子乙素共载脂质体克服肿瘤多药耐药机制.方法 制备多柔比星-五味子乙素共载脂质体,以人慢性髓系白血病耐药细胞株K562/DOX为模型细胞,分别探讨不同温度、内吞抑制剂存在下的细胞摄取药物的情况,并检测耐药细胞P-gp表达和细胞凋亡情况.结果 共载脂质体在4℃及氯喹、叠氮钠和甘露醇内吞抑制剂存在下进入耐药细胞的药物量明显减少;流式细胞仪检测多柔比星-五味子乙素共载脂质体可抑制P-gp表达且诱导凋亡.结论 多柔比星-五味子乙素共载脂质体进入K562/DOX细胞主要通过耗能的内吞途径;而多柔比星-五味子乙素共载脂质体克服肿瘤多药耐药可能是通过抑制P-gp表达和促进凋亡双通道途径.“,”OBJECTIVE To investigate the mechanism of doxorubicin-schisandrin B co-delivery liposomes(DSCL) to overcome multidrug resistance(MDR).METHODS DSCL were prepared.The K562/DOX cells were chosen as the model cells.The low temperature test,Endocytosis inhibitors (chloroquine,sodium azide,and mannitol) test were carded out on K562/DOX cells.And P-gp expression and apoptosis were detected by flow cytometry.RESULTS The uptake of DSCL was energy-dependent and was influenced by temperature,and endocytosis inhibitors,such as chloroquine,sodium azide and mannitol,could decrease significantly accumulation of DOX.The flow cytometry result revealed that the expression of P-gp of K562/DOX cells was significantly inhibited after treatment with DSCL,and it showed DSCL induced a regulated apoptotis in cells.CONCLUSION DSCL were uptaken through the endocytosis of energy-dependent.It is proposed the mechanism of DSCL to overcome multidrug resistance was a dual strategy by inhibiting the expression of P-gp and promoting apoptotis.